Andrew D. Wilcock, PhD; Lee H. Schwamm, MD; Jose R. Zubizarreta, PhD; et al.
free access
has audio
JAMA Neurol. 2021;78(5):527-535. doi:10.1001/jamaneurol.2021.0023
This study describes differences in care patterns and outcomes among patients with acute ischemic stroke who present to hospitals with and without telestroke capacity.
-
Podcast:
Reperfusion Treatment and Stroke Outcomes in Hospitals with Telestroke Capacity
Kerri L. LaRovere, MD; Becky J. Riggs, MD; Tina Y. Poussaint, MD; et al.
free access
JAMA Neurol. 2021;78(5):536-547. doi:10.1001/jamaneurol.2021.0504
This study evaluates the range and severity of neurologic involvement among children and adolescents associated with COVID-19.
Robert G. Kowalski, MBBCh, MS; Flora M. Hammond, MD; Alan H. Weintraub, MD; et al.
free access
JAMA Neurol. 2021;78(5):548-557. doi:10.1001/jamaneurol.2021.0084
This cohort study analyzes the neuroanatomic, functional, and other outcomes during the emergent, critical care, and rehabilitation phases after new-onset traumatic brain injury with disrupted consciousness.
Ludwig Kappos, MD; Robert J. Fox, MD; Michel Burcklen, PhD; et al.
open access
JAMA Neurol. 2021;78(5):558-567. doi:10.1001/jamaneurol.2021.0405
This superiority study compares the efficacy of ponesimod, a selective sphingosine-1-phosphate receptor 1 modulator with teriflunomide, a pyrimidine synthesis inhibitor, approved for the treatment of patients with relapsing multiple sclerosis.
Ilya M. Nasrallah, MD, PhD; Sarah A. Gaussoin, MS; Raymond Pomponio, BS; et al.
free access
JAMA Neurol. 2021;78(5):568-577. doi:10.1001/jamaneurol.2021.0178
This secondary analysis of a randomized clinical trial evaluates the association of intensive blood pressure control on Alzheimer disease鈥搑elated brain biomarkers.
Yi Li, MD; Wesley K. Thompson, PhD; Chase Reuter, MS; et al.
free access
JAMA Neurol. 2021;78(5):578-587. doi:10.1001/jamaneurol.2021.0306
This cohort study examines the prevalence of incidental findings identified on brain magnetic resonance imaging in children from the general population.
Elan L. Guterman, MD; John P. Betjemann, MD; Alex Aimetti, PhD; et al.
free access
JAMA Neurol. 2021;78(5):588-595. doi:10.1001/jamaneurol.2021.0520
This cross-sectional study compares the outcomes and costs of treatments among patients with low, moderate, and highly refractive status epilepticus.